Novo Nordisk A/S

About Novo Nordisk A/S

Novo Nordisk is a global pharmaceutical company selling prescription medicines, with its principal commercial exposure in diabetes and obesity care. Its portfolio includes semaglutide-based therapies and other treatments serving patients through physicians, pharmacies, insurers and national healthcare systems; the supplied evidence also highlights pediatric obesity development. Diabetes and obesity products are the central growth engines, while other biopharmaceutical medicines provide additional revenue, although no segment contribution figures are supplied. Novo earns money primarily from medicine sales rather than services, and operates at global scale, competing directly with Eli Lilly in the expanding GLP-1 market.

Notable Price Movement

1. Sep 7-11$43.077.58%

   Novo Nordisk fell $0.17, or 0.38%, from $45.33 to $45.16 over the week. Trading was volatile rather than steadily directional: the stock slipped to $45.12 on September 1, then rallied to $46.77 and $47.51 on September 2-3 before giving back part of the advance on September 4 and most of it in the final observed session. Coverage around the move focused on concern over two halted or cancelled trials, despite positive pediatric semaglutide data, and Morgan Stanley’s bearish view that Eli Lilly is taking market share and that Novo’s weight-loss franchise carries increasing risk. The evidence does not identify a broader market catalyst or quantify its effect.

   28 sources
2. Aug 31 - Sep 4$46.602.17%

   Novo Nordisk rose 2.70% over the reference period, from $46.26 to $47.51, although trading during the week began at $45.33. Shares fell on Monday and Tuesday, reaching $45.12, before reversing sharply on Wednesday and adding again Thursday. The late-week rebound coincided with coverage that pressure from a low-cost GLP-1 rival was easing and with renewed attention to Novo’s valuation, including GuruFocus’s view that the stock remained undervalued. Reports on progress toward the company’s DKK15 billion buyback may also have supported sentiment. The evidence does not identify a single confirmed company announcement driving the move, while the broader backdrop remained focused on intensifying obesity-drug competition and Novo’s efforts to close Eli Lilly’s lead.

   22 sources
3. Aug 24-28$45.612.42%

   Novo Nordisk fell 2.42% over the week, from $46.74 to $45.61. The stock initially gained modestly on Monday, then rallied 3.71% on Tuesday to $48.66, with volume rising to 15.5 million shares. Coverage citing an analyst target increase and Wegovy momentum, along with a separate report on upgraded JPMorgan sales estimates, provided the clearest positive backdrop, although the supplied evidence does not identify the revised targets or timing. Shares reversed over the remainder of the week, declining on Wednesday, Thursday and Friday and giving back more than the Tuesday advance. No dated company-specific announcement in the evidence fully explains the reversal, which appears to reflect fading momentum and changing analyst sentiment.

   24 sources
4. Aug 10-14$45.892.90%

   Novo Nordisk rose $0.64, or 1.36%, from $47.09 on August 3 to $47.73 on August 10, but the headline gain masks a sharp reversal. Shares plunged $2.81, or 5.97%, to $44.28 on August 4 on 47.5 million shares, then recovered steadily through August 10. The recovery followed second-quarter commentary showing 7% adjusted sales growth at constant exchange rates and GLP-1 volume growth across obesity and diabetes, although lower realized prices and continuing growth doubts limited the interpretation. Zacks Research’s move to Hold also reinforced a cautious tone. The stock recovered all of the early-week decline without a separate, clearly identified catalyst, leaving the net move modestly positive.

   28 sources
5. Aug 3-7$47.260.38%

   Novo Nordisk fell $6.68, or 13.11%, from $50.96 to $44.28 over the measured week. The main catalyst was disappointing ZEUS Phase 3 results: ziltivekimab showed success on the IL-6 pathway but failed to reduce cardiovascular events, prompting the sharpest decline on July 31, when shares dropped from $51.61 to $47.08 on 26.8 million shares and broke below the cited $47.00 200-day moving average. Selling intensified on August 4, with the stock losing another $2.81 to $44.28 on record-period volume of 47.5 million shares. Pre-Q2 uncertainty added pressure, as coverage cited slowing injectable GLP-1 momentum, pricing headwinds and competition. Broader market context was comparatively supportive, with the Nasdaq-100 pre-market indicator higher in the supplied observations.

   11 sources

Stories & Analysis

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European UnionZacks · 2d agoWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY LeadRTTNews · 2d agoNovo's Sogroya Gets Positive EU Opinion For Children With Idiopathic Short StatureRTTNews · 2d agoA weekly shot may become Europe’s first approved growth-hormone treatment for children with unexplained shortnessStock Titan · 2d agoOrbis Medicines Partners With Novo In Up To $1.4 Billion Drug Discovery DealRTTNews · 2d agoSandoz Wins Canadian Marketing Approval For Generic Semaglutide InjectionRTTNews · 2d agoNovo Nordisk (NVO) Pulls the Plug on Two More Heart Drug TrialsYahoo Finance · 2d agoNVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia PenStocktwits · 2d ago